Anette Karle, PhD

Novartis Biologics Center

Basel, Switzerland

Immunogenicity against biotherapeutic drugs, an immune response, which could result in the formation of anti-drug antibodies and drug-specific T cells, is a common effect, which can have an impact on the efficacy of the biotherapeutic and the safety of the patient. Our work is focused on understanding the immune mechanisms that contribute to the development of immunogenicity and downstream effects. We are applying state of the art immunology, proteomics and molecular biology technologies on human samples derived from healthy volunteers and patients from clinical trials. We are working in a highly collaborative environment with many groups at Novartis Institutes for Biomedical Research and Global Drug Development, connecting also with academic university hospitals. A human translational sciences approach will provide new insights for the development of transformative medicines with a better safety and efficacy profile.


Selected Publications

Applying MAPPs Assays to Assess Drug Immunogenicity.
Karle, A. C.
Front Immunol. 2020 Apr ; 11: 698.

T cell epitope mapping of secukinumab and ixekizumab in healthy donors.
Spindeldreher, S., A. Karle, E. Correia, M. Tenon, S. Gottlieb, T. Huber, B. Maillere and F. Kolbinger
MAbs 2020. 12(1): 1707418.

Tregitopes and impaired antigen presentation: Drivers of the immunomodulatory effects of IVIg? 
Sorde L, Spindeldreher S, Palmer E, Karle A. 
Immun Inflamm Dis. 2017 Dec.;5(4):400-15.

Click here for additional publications.